





# Recombinant Human C-C chemokine receptor type 2 (CCR2) (Active)

<b>Product Code</b>	CSB-CF004841HU
<b>Relevance</b>	Receptor for the CCL2, CCL7 and CCL13 chemokines. Receptor for the beta-defensin DEFB106A/DEFB106B. Transduces a signal by increasing intracellular calcium ion levels. Upon CCL2 ligation, mediates chemotaxis and migration induction through the activation of the PI3K cascade, the small G protein Rac and lamellipodium protrusion (Probable).
<b>Storage</b>	The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
<b>Uniprot No.</b>	P41597
<b>Storage Buffer</b>	Tris-based buffer, 50% glycerol
<b>Product Type</b>	Others
<b>Immunogen Species</b>	Homo sapiens (Human)
<b>Biological Activity</b>	Measured by its binding ability in a functional ELISA. Immobilized CCR2 at 1 µg/ml can bind human CCL2, the EC50 of human CCL2 protein is 41.51-83.15 µg/ml.
<b>Purity</b>	Greater than 85% as determined by SDS-PAGE.
<b>Sequence</b>	MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFI FGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGN AMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLV AVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLP LLIMVICY SGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFGLSNCE STSQLDQATQVTETLGMTHCCINPIYAFVGEKFRSLFHIALGCRIAPLQKPVCG GPGVRPGKNVKVTTQGLLDGRGKGKSGRAPEASLQDKEGA
<b>Research Area</b>	Cancer
<b>Source</b>	in vitro E.coli expression system
<b>Gene Names</b>	CCR2
<b>Expression Region</b>	1-374aa
<b>Notes</b>	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
<b>Tag Info</b>	N-terminal 10xHis-tagged
<b>Mol. Weight</b>	45.4 kDa
<b>Protein Description</b>	Full Length
<b>Image</b>	



(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.



## Description

The recombinant human C-C chemokine receptor type 2 (CCR2) protein is a cell-free system in vitro E.coli expressed full-length protein with good activity. In cell-free systems, the plasmid vector containing the gene that encodes the full-length CCR2 protein (1-374aa) can be induced to express the protein in vitro using extracts of whole cells that are compatible with translation. The purity of this recombinant human CCR2 protein is greater than 85% as measured by SDS-PAGE. Its activity has been validated in a functional ELISA.

CCR2 is a protein found on certain immune cells like monocytes and macrophages, guiding them to areas of injury and inflammation [1]. It interacts with different proteins like CCL2, CCL7, CCL8, CCL12, and CCL13 [2]. When CCR2 is activated, it triggers signals inside cells that control how they stick to surfaces and move around, especially in macrophages [3]. This protein is crucial for bringing inflammatory cells to sites of inflammation and also plays a part in bone cell development [4][5]. It's involved in various health conditions, including cancer, kidney injuries, cognitive problems from head radiation, and heart failure [6][7][8][9]. Scientists have found that CCR2 might affect inflammation, brain cell growth, brain cell activity, and thinking abilities [6]. In breast cancer, CCR2 seems to help cancer cells grow and spread [10]. It also helps regulate levels of certain signaling molecules in the blood [11]. Some researchers think that targeting the CCL2–CCR2 pathway could be a way to treat traumatic brain injuries [12].

## References:

[1] F. Kumase, K. Takeuchi, Y. Morizane, J. Suzuki, H. Matsumoto, K. Kataoka et al., Ampk-activated protein kinase suppresses ccr2 expression by inhibiting the nf-kb pathway in raw264.7 macrophages, Plos One, vol. 11, no. 1,



- p. e0147279, 2016. <https://doi.org/10.1371/journal.pone.0147279>
- [2] L. Xu, Q. Fang, Y. Miao, M. Xu, Y. Wang, L. Sun et al., The role of ccr2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling, *Bioengineered*, vol. 12, no. 1, p. 3467-3484, 2021. <https://doi.org/10.1080/21655979.2021.1947631>
- [3] W. Fang, I. Jokar, A. Zou, D. Lambert, P. Dendukuri, & N. Cheng, Ccl2/ccr2 chemokine signaling coordinates survival and motility of breast cancer cells through smad3 protein- and p42/44 mitogen-activated protein kinase (mapk)-dependent mechanisms, *Journal of Biological Chemistry*, vol. 287, no. 43, p. 36593-36608, 2012. <https://doi.org/10.1074/jbc.m112.365999>
- [4] R. Cherney, R. Mo, M. Yang, Z. Xiao, Q. Zhao, S. Mandlekaret al., Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (ccr2) antagonists, *Bioorganic & Medicinal Chemistry Letters*, vol. 24, no. 7, p. 1843-1845, 2014. <https://doi.org/10.1016/j.bmcl.2014.02.013>
- [5] Z. Xing, C. Lu, D. Hu, Y. Yu, X. Wang, C. Colnot et al., Multiple roles for ccr2 during fracture healing, *Disease Models & Mechanisms*, vol. 3, no. 7-8, p. 451-458, 2010. <https://doi.org/10.1242/dmm.003186>
- [6] K. Bélarbi, T. Jopson, C. Arellano, J. Fike, & S. Rosi, Ccr2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation, *Cancer Research*, vol. 73, no. 3, p. 1201-1210, 2013. <https://doi.org/10.1158/0008-5472.can-12-2989>
- [7] P. Mittal, L. Wang, T. Akimova, C. Leach, J. Clemente, M. Senderet al., The ccr2/mcp-1 chemokine pathway and lung adenocarcinoma, *Cancers*, vol. 12, no. 12, p. 3723, 2020. <https://doi.org/10.3390/cancers12123723>
- [8] K. Furuichi, T. Wada, Y. Iwata, K. Kitagawa, K. Kobayashi, H. Hashimoto et al., Ccr2 signaling contributes to ischemia-reperfusion injury in kidney, *Journal of the American Society of Nephrology*, vol. 14, no. 10, p. 2503-2515, 2003. <https://doi.org/10.1097/01.asn.0000089563.63641.a8>
- [9] G. Bajpai, C. Schneider, N. Wong, A. Bredemeyer, M. Hulsmans, M. Nahrendorf et al., The human heart contains distinct macrophage subsets with divergent origins and functions, *Nature Medicine*, vol. 24, no. 8, p. 1234-1245, 2018. <https://doi.org/10.1038/s41591-018-0059-x>
- [10] G. Brummer, W. Fang, C. Smart, B. Zinda, N. Alissa, C. Berkland et al., Ccr2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting ccl2 and suppressing cd154 effects on the angiogenic and immune microenvironments, *Oncogene*, vol. 39, no. 11, p. 2275-2289, 2019. <https://doi.org/10.1038/s41388-019-1141-7>
- [11] B. Zhao, J. Campbell, C. Salanga, L. Ertl, Y. Wang, S. Yau et al., Ccr2-mediated uptake of constitutively produced ccl2: a mechanism for regulating chemokine levels in the blood, *The Journal of Immunology*, vol. 203, no. 12, p. 3157-3165, 2019. <https://doi.org/10.4049/jimmunol.1900961>
- [12] Y. Jiang, Y. Chen, C. Huang, A. Xia, G. Wang, & S. Liu, Hyperbaric oxygen therapy improves neurological function via the p38-mapk/ccl2 signaling pathway following traumatic brain injury, *Neuroreport*, vol. 32, no. 15, p. 1255-1262, 2021. <https://doi.org/10.1097/wnr.0000000000001719>